The present application disclosed a process for the preparation of ethyl 3-(2-((4-cyanophenylamino) methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d] imidazole-5-carboxamido) propionate, compound of formula II an intermediate of Dabigatran.

The present application disclosed a process for the preparation of 4-hydroxypiperidine compound of formula I by reducing compound of formula II with Raney Ni.

The present application disclosed a process for the preparation of Mebeverine and its pharmaceutically acceptable salts.

The present application disclosed a process for the preparation of 4-hydroxybenzothioamide an intermediate of Febuxostat.

The present application disclosed a process for the preparation of 7-(4-halobutoxy)-3,4-dihydro-2(1H)-quinolinone of formula A an intermediate of Aripiprazole. wherein, X is a halogen selected from the group consisting of chloro, bromo and iodo.

The present application disclosed a process for the preparation of 1,3-dialkylpiperidin-4-one of compound of formula I and 1,3-dimethylpiperidin-4-one.

The present application disclosed a process for the preparation of 2-halo-5,6-diphenyl-1,4-pyrazine, an intermediate of Selexipag. Wherein, X is a halogen selected from the group consisting of chloro, bromo and iodo.

The present application disclosed a process for the preparation of 4-halobutyl-3,4-dimethoxybenzoateof formula A, an intermediate of Mebeverine. wherein, X is a halogen selected from the group consisting of chloro, bromo and iodo.

The present application disclosed a process for the preparation of Nebivolol epoxide intermediate using enzymatic resolution.

The present application disclosed a process for the preparation of Mebeverine using water as a solvent.

The present application disclosed a process for the purification of Nortriptyline by reducing N-nitroso impurity.

Abstract The present application discloses a process for the preparation of intermediates of Brigatinib.

Abstract The present application discloses a process for the preparation of 4-benzamido piperidine.